ImmunoPrecise Antibodies Ltd. announced the appointment of Kristin Taylor as Chief Financial Officer, effective immediately. Ms. Taylor has been serving as Interim CFO since September 19, 2023, and now transitions into the role on a permanent basis. Ms. Taylor is a seasoned financial executive with extensive experience in both early-stage and large growth companies, including those privately held, private equity-backed, and publicly listed.

She has a strong background in driving growth, establishing infrastructure, and implementing effective strategies for value creation in dynamic, scaling environments. Prior to joining IPA, Ms. Taylor served as the Chief Financial Officer of Bay West LLC and B-MoGen Biotechnologies Inc., along with capital markets and liquidity management roles at Prime Therapeutics and Medtronic. Previous to her corporate experience, she held technical and consulting roles in public accounting.

Her expertise spans growth strategies and execution, fundraising and recapitalizations, due diligence and acquisition integration, financial analysis, accounting, audit and tax compliance, staff leadership and development, process development and IT initiatives, and board and investor relations. Ms. Taylor holds an MBA in Finance and Strategic Management from the Carlson School of Management at the University of Minnesota, where she was a Carlson Scholar, and a Bachelor of Science in Business Administration with a Major in Accounting and a Minor in Communications. She is also a Certified Public Accountant (inactive).